Vator Securities advises Magle Group on 27 MSEK Capital Raise
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise, Magle PharmaCept – an established sales and marketing company for development and direct sales of the Group’s medical technology products and Magle Biopolymers A/S – a specialized manufacturing organization of Dextran technology.
The proceeds from the Directed Share Issue are intended to be used to advance key projects that reinforce Magle Group’s position in innovative medical solutions and support the group’s ongoing structural and organisational changes following recent mergers.
Read More
Vator Securities advises Alligator Bioscience on 280 MSEK Capital Raise
Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer.
Its portfolio includes lead drug candidate mitazalimab, for which the company reported unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in Phase 2 testing and is in preparation for Phase 3 development.
Read More
Vator Securities advises Magle Group on 37 MSEK Capital Raise
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk.
Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise, Magle PharmaCept – an established sales and marketing company for development and direct sales of the Group’s medical technology products and Magle Biopolymers A/S – a specialized manufacturing organization of Dextran technology.
Read More
Vator Securities advises Agtira on 60 MSEK Capital Raise
Agtira offers its Farming as a Service (FaaS) approach to food chains, shops and other stakeholders. This means that Agtira invests, builds and then operates its farming systems for the production of a range of vegetables and fish species, either by itself or together with a third party, while the store or chain undertakes to buy the entire volume produced over a certain contractual period at predetermined prices.
What Agtira’s farming systems have in common is that they produce food with low water consumption in closed environments, with no emissions to the local environment or need for agricultural land. Growing in urban environments also means reducing the need for transportation and reducing waste.
Read More
Vator Securities advises Q-linea on 225 MSEK Capital Raise
Q-linea is an innovative infection diagnostics company that develops instruments and disposables for rapid and reliable infection diagnostics. Q-linea’s first product, ASTar, has in completed studies shown to be able to determine which antibiotics are effective against an infection, so-called AST analysis, significantly faster than other methods.
ASTar was launched on the European market in the autumn of 2021 and after the Company received market approval for the US market on April 26, 2024, ASTar has also been launched in the US.
Read More
Vator Securities advises Ziccum on 30 MSEK Capital Raise
Ziccum is developing LaminarPace®, a unique drying method for biopharmaceuticals and vaccines based on mass transfer, not heat transfer. The technology is offered by licensing to vaccine and biologics developers and manufacturers in the global pharmaceutical industry.
By reducing drying stress to the active ingredient, LaminarPace® uniquely enables particle-engineered, thermostable dry powder biopharmaceuticals which can be easily handled and transported and are highly suitable for novel administration routes. The technology has successfully been applied to mRNA, peptides, proteins, antibodies, lipids and enzymes as well as excipients and adjuvants, and is well suited for industrial application.
Read More
Vator Securities advises Gaming Corps on 32 MSEK Capital Raise
Gaming Corps AB is a development company that operates in the global digital gaming market by developing casino games within iGaming. The Company was founded in 2014 and has been listed on Nasdaq First North Growth Market since 2015.
Gaming Corps is based in Uppsala and has wholly owned subsidiaries in Malta, from which employees work remotely and where all game development takes place. Operations focus on several categories of casino games: Casino Slots, Table Games, Multiplier Games, Mine Games and Smash4cash. The Company works mainly with two business models, the first of which consists of the development of non-exclusive games that can be offered to more than one operator. The second business model relates to the development of tailor-made and/or exclusive games for individual operators, as well as various levels of branding and theme customization based on their needs.
Read More
Vator Securities advises Moberg Pharma on 336 MSEK Capital Raise
Moberg Pharma AB (publ) is a Swedish pharmaceutical company focused on commercializing proprietary innovations based on drug delivery of proven compounds. The Company’s asset, MOB-015, is a novel topical treatment for onychomycosis with market approval in 13 EU countries.
MOB-015 is available in Sweden under the brand name Terclara®. Moberg Pharma has agreements with commercial partners in place in various regions including Europe and Canada.
Read More